On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- MHLW Urges Generic Drug Makers to Ensure Availability of Products for All Indications Approved for Original Drugs
April 6, 2012
- MHLW to Issue 80 Requests for Development of Unapproved Drugs/Indications This Week
April 5, 2012
- Japan to Maintain Drug Pricing System in TPP Talks: Health Minister Komiyama
April 4, 2012
- MHLW Presents Standard Time Frames for Drug Approval Process by Individual Procedure
April 3, 2012
- PMDA Strengthens Consultation System to Support Biomarker Development
April 3, 2012
- MHLW Prepares Q&A to Address Healthcare Professionals’ Concerns About Generic Drugs
April 3, 2012
- DPJ’s PAL Subcommittee to Hold Off Final Recommendation on PAL Amendment Until Late April
April 2, 2012
- MHLW Approves 10 Products Including Pfizer Japan’s Xalkori
April 2, 2012
- CSIMC Recommends Approval of Insurance Coverage for Diagnosis for Xalkori Administration
March 30, 2012
- MHLW Proposes Pricing of Long-Listed Products to Be Concluded in FY2013: CSIMC Meeting
March 30, 2012
- CSIMC to Discuss Introduction of Medicoeconomic Assessment in FY2014
March 30, 2012
- MHLW Issues Safety Warning on Use of Afinitor in HBV Carriers
March 30, 2012
- Office of Medical Innovation Begins Discussions on “Five-year Strategy for Medical Innovation”, Compiles Interim Report by Mid-April
March 29, 2012
- “MHLW Ideal” Placement for Drug Discovery Support Organization: Medical Innovation Office Counselor Hachiyama
March 28, 2012
- Handling of Adverse Reaction Data an Issue in Access System Adaptation: MHLW Deputy Director Miyata
March 28, 2012
- Eight Products/Indications Including Xalkori to Receive Formal Approval by End of Month
March 28, 2012
- Use of Medicoeconomic Assessment in Drug Pricing “Unrealistic”: DG for Policy Planning and Evaluation Katori
March 28, 2012
- MHLW Study Group Decides on Next 5-Year Plan for Activation of Clinical Research
March 27, 2012
- Council for Improvement of the Distribution of Ethical Drugs Agrees to Establish Working Team, Focus on Spreading “Mutual Understanding”
March 27, 2012
- “No Serious ADR” Found in MHLW’s Fixed-Point Observation for Byetta
March 27, 2012
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…